Ablynx's osteoporosis nanobody enters clinic
This article was originally published in Scrip
Executive Summary
Ablynx of Belgium has began clinical testing of a fourth nanobody, ALX-0141, for the treatment of osteoporosis. ALX-0141 targets Receptor Activator of Nuclear Factor kappa B Ligand (RANKL), a key regulator of bone resorption.